Green tea polyphenol EGCG reverse cisplatin resistance of A549/DDP cell line through candidate genes demethylation

Biomedicine and Pharmacotherapy

Volumn 69, Issue , 2015, Pages 285-290

  Zhang, Youwei ^a   Wang, Xiang ^a   Han, Liang ^a   Zhou, Yizhou ^a   Sun, Sanyuan ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Cisplatin; Epigallocatechin 3 gallate; Lung cancer; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; DNA; DNA METHYLTRANSFERASE; EPIGALLOCATECHIN GALLATE; HISTONE DEACETYLASE; CATECHIN; POLYPHENOL; TEA;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL PROLIFERATION; CHEMOSENSITIVITY; COLONY FORMATION; COMPARATIVE EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; DRUG EXPOSURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GAS1 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; ICAM1 GENE; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TEA; TIMP4 GENE; TREATMENT DURATION; WISP2 GENE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; NUDE MOUSE; TUMOR CELL LINE; TUMOR GENE;

ANIMALS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENES, NEOPLASM; HUMANS; MICE, INBRED BALB C; MICE, NUDE; POLYPHENOLS; TEA;

EID: 84922227196     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.016     Document Type: Article

References (31)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63:12-31.
4. Marsh S., McLeod H., Dolan E., Shukla S.J., Rabik C.A., Gong L., et al. Platinum pathway. Pharmacogenet Genomics 2009, 19:563-564.
5. Zeller C., Dai W., Steele N.L., Siddiq A., Walley A.J., Wilhelm-Benartzi C.S., et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012, 31:4567-4576.
6. Chang X., Monitto C.L., Demokan S., Kim M.S., Chang S.S., Zhong X., et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 2010, 70:2870-2879.
7. Zhang Y.W., Zheng Y., Wang J.Z., Lu X.X., Wang Z., Chen L.B., et al. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics 2014, 9:896-909.
8. Balch C., Nephew K.P. Epigenetic targeting therapies to overcome chemotherapy resistance. Adv Exp Med Biol 2013, 754:285-311.
9. Yang G., Zheng W., Xiang Y.B., Gao J., Li H.L., Zhang X., et al. Green tea consumption and colorectal cancer risk: a report from the Shanghai Men's Health Study. Carcinogenesis 2011, 32:1684-1688.
10. Singh B.N., Shankar S., Srivastava R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011, 82:1807-1821.
11. Lambert J.D., Sang S., Hong J., Yang C.S. Anticancer and anti-inflammatory effects of cysteine metabolites of the green tea polyphenol, (-)-epigallocatechin-3-gallate. J Agric Food Chem 2010, 58:10016-10019.
12. Moseley V.R., Morris J., Knackstedt R.W., Wargovich M.J. Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. Anticancer Res 2013, 33:5325-5333.
13. Ibanez de Caceres I., Cortes-Sempere M., Moratilla C., Machado-Pinilla R., Rodriguez-Fanjul V., Manguán-García C., et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 2010, 29:1681-1690.
14. Csepregi A., Ebert M.P., Röcken C., Schneider-Stock R., Hoffmann J., Schulz H.U., et al. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer 2010, 10:317.
15. Toyota M., Suzuki H., Yamashita T., Hirata K., Imai K., Tokino T., et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci 2009, 100:787-791.
16. Vendetti F.P., Rudin C.M. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opin Biol Ther 2013, 13:1273-1285.
17. Navada S.C., Steinmann J., Lübbert M., Silverman L.R. Clinical development of demethylating agents in hematology. J Clin Invest 2014, 124:40-46.
18. West A.C., Johnstone R.W. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014, 124:30-39.
19. Ahuja N., Easwaran H., Baylin S.B. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 2014, 124:56-63.
20. Quagliana J.M., O'Bryan R.M., Baker L., Gottlieb J., Morrison F.S., Eyre H.J., et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep 1977, 61:51-54.
21. Azad N., Zahnow C.A., Rudin C.M., Baylin S.B. The future of epigenetic therapy in solid tumours - lessons from the past. Nat Rev Clin Oncol 2013, 10:256-266.
22. Juergens R.A., Wrangle J., Vendetti F.P., Murphy S.C., Zhao M., Coleman B., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011, 1:598-607.
23. Matei D., Fang F., Shen C., Schilder J., Arnold A., Zeng Y., et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012, 72:2197-2205.
24. Fu S., Hu W., Iyer R., Kavanagh J.J., Coleman R.L., Levenback C.F., et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011, 117:1661-1669.
25. Campbell R.M., Tummino P.J. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest 2014, 124:646-649.
26. Chen D., Wan S.B., Yang H., Yuan J., Chan T.H., Dou Q.P. EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem 2011, 53:155-177.
27. Fang M.Z., Wang Y.W., Ai N., Hou Z., Sun Y., Lu H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003, 63:7563-7570.
28. Kato K., Long N.K., Makita H., Toida M., Yamashita T., Hatakeyama D., et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br J Cancer 2008, 99:647-654.
29. Thakur V.S., Gupta K., Gupta S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis 2012, 33:377-384.
30. Tachibana H. Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr 2009, 61:156-169.
31. Yeo W., Chung H.C., Chan S.L., Wang L.Z., Lim R., Picus J., et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012, 30:3361-3367.